DE60129229D1 - Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren - Google Patents

Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren

Info

Publication number
DE60129229D1
DE60129229D1 DE60129229T DE60129229T DE60129229D1 DE 60129229 D1 DE60129229 D1 DE 60129229D1 DE 60129229 T DE60129229 T DE 60129229T DE 60129229 T DE60129229 T DE 60129229T DE 60129229 D1 DE60129229 D1 DE 60129229D1
Authority
DE
Germany
Prior art keywords
delivery
muscle
raav
associated virus
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129229T
Other languages
English (en)
Other versions
DE60129229T2 (de
Inventor
Keiya Ozawa
Masahisa Shimpo
Uichi Ikeda
Yoshikazu Maeda
Kazuyuki Shimada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE60129229D1 publication Critical patent/DE60129229D1/de
Application granted granted Critical
Publication of DE60129229T2 publication Critical patent/DE60129229T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE60129229T 2000-08-17 2001-08-17 Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren Expired - Lifetime DE60129229T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22605600P 2000-08-17 2000-08-17
US226056P 2000-08-17
PCT/IB2001/001902 WO2002014487A2 (en) 2000-08-17 2001-08-17 Adeno-associated virus-mediated delivery of angiogenic factors

Publications (2)

Publication Number Publication Date
DE60129229D1 true DE60129229D1 (de) 2007-08-16
DE60129229T2 DE60129229T2 (de) 2008-05-08

Family

ID=22847367

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129229T Expired - Lifetime DE60129229T2 (de) 2000-08-17 2001-08-17 Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren

Country Status (9)

Country Link
US (2) US20020111324A1 (de)
EP (1) EP1311699B1 (de)
JP (1) JP2004506658A (de)
AT (1) ATE366319T1 (de)
AU (1) AU2001294096A1 (de)
CA (1) CA2419245A1 (de)
DE (1) DE60129229T2 (de)
ES (1) ES2288993T3 (de)
WO (1) WO2002014487A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157064A1 (en) * 2001-11-09 2003-08-21 Pascal Neuville Chimeric promoters for controlling expression in muscle cells
EP1490107A4 (de) * 2002-03-21 2005-11-09 Univ Florida Modulation der angiogenese
US20030198620A1 (en) * 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
CN100387723C (zh) * 2005-12-02 2008-05-14 浙江大学 血管生长素基因重组腺相关病毒载体及制备方法和用途
GB0821834D0 (en) * 2008-11-28 2009-01-07 Iti Scotland Ltd Calibration and control method
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CA2966620A1 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016112049A1 (en) * 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
WO2016133848A2 (en) 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
KR102392236B1 (ko) 2016-05-18 2022-05-03 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
WO2020069461A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2022026410A2 (en) 2020-07-27 2022-02-03 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764893A (ja) * 1993-08-31 1995-03-10 Canon Inc ネットワーク・システム
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
AU1980697A (en) * 1996-03-04 1997-09-22 Targeted Genetics Corporation Methods for transducing cells in blood vessels using recombinant AAV vec tors
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
NZ505955A (en) * 1998-02-06 2005-04-29 Collateral Therapeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use
AU763049B2 (en) * 1998-12-28 2003-07-10 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
JP2003501092A (ja) * 1999-06-07 2003-01-14 エドワーズ ライフサイエンシーズ コーポレイション 標的化新脈管形成
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder

Also Published As

Publication number Publication date
US20070128163A1 (en) 2007-06-07
EP1311699B1 (de) 2007-07-04
EP1311699A2 (de) 2003-05-21
CA2419245A1 (en) 2002-02-21
DE60129229T2 (de) 2008-05-08
US20020111324A1 (en) 2002-08-15
ES2288993T3 (es) 2008-02-01
AU2001294096A1 (en) 2002-02-25
JP2004506658A (ja) 2004-03-04
WO2002014487A2 (en) 2002-02-21
ATE366319T1 (de) 2007-07-15
WO2002014487A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE60129229D1 (de) Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
ATE312176T1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
BR9609303B8 (pt) Vírus de vaccinia ankara modificado (mva), recombinante, bem como vacina contendo o mesmo.
JP2004506658A5 (de)
CL2020000295A1 (es) Métodos de terapia génica del factor viii (fviii)
NO993669D0 (no) Flersteds avlevering av adenoviral vektor for induksjon av angiogenese
WO2002004623A3 (en) ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
NO20044940L (no) Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet
WO2001096587A3 (en) Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
DE60332011D1 (de) Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
EA200200533A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo
Nesbit Abrogation of tumor vasculature using gene therapy
WO2002063025A3 (en) Muscle-directed gene therapy with aav-1 and aav-6 vectors
CA2451311A1 (en) Stimulation of vascularization with vegf-b
CO2022002864A2 (es) Administración de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular
BR0012556A (pt) Genes e vacinas de ehrlichia canis
WO2002085289A3 (en) Modulators of angiogenesis
DK1556494T3 (da) Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf
WO2002088319A3 (en) Mini-adenoviral vector and methods of using same
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition